---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-25-000026"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:35:41.278724+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma initiates Phase 2 Seabreeze STAT study of rademikibart for acute asthma exacerbations

## Summary
- Phase 2 Seabreeze STAT Asthma study (NCT06940141) initiated after FDA agreement on final protocol.
- Evaluates rademikibart as adjunct to standard of care in ~160 adults/adolescents with type 2 inflammation asthma.
- Primary endpoint: treatment failure rate over 28 days; secondary include exacerbations and lung function.
- Topline data expected in first half of 2026.
- Imminently on track to initiate a similarly-designed Phase 2 study in COPD.

## SEC filing metadata
- accession: 0001835268-25-000026
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000026/0001835268-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000026/cntb-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-25-000026
- JSON: https://secwatch.observer/filing/0001835268-25-000026.json
- Plain text: https://secwatch.observer/filing/0001835268-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.